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In Brief
Glucose consumption by antigenic
tumors can metabolically restrict T cells,
directly dampening their effector function
and allowing tumor progression.
Checkpoint blockade therapy may
correct this resource imbalance through a
direct effect in the tumor cells.
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Failure of T cells to protect against cancer is thought
to result from lack of antigen recognition, chronic
activation, and/or suppression by other cells. Using
a mouse sarcoma model, we show that glucose con-
sumption by tumors metabolically restricts T cells,
leading to their dampened mTOR activity, glycolytic
capacity, and IFN-g production, thereby allowing
tumor progression. We show that enhancing glycol-
ysis in an antigenic ‘‘regressor’’ tumor is sufficient
to override the protective ability of T cells to control
tumor growth. We also show that checkpoint
blockade antibodies against CTLA-4, PD-1, and
PD-L1, which are used clinically, restore glucose
in tumor microenvironment, permitting T cell glycol-
ysis and IFN-g production. Furthermore, we found
that blocking PD-L1 directly on tumors dampens
glycolysis by inhibitingmTORactivity anddecreasing
expression of glycolysis enzymes, reflecting a role for
PD-L1 in tumor glucose utilization. Our results estab-
lish that tumor-imposed metabolic restrictions can
mediate T cell hyporesponsiveness during cancer.INTRODUCTION
Establishing why some cancers progress while others do not is a
longstanding challenge in immunology. Destruction of strongly
immunogenic tumors is a critical part of the antitumor immune
response. However, cancers that express weakly immunogenic
antigens evade killing and this can be a primary mechanism of
tumor progression (Vesely and Schreiber, 2013). Tumors are
also known to escape immunity via T cell dysfunction or hypores-
ponsiveness. Anergy, exhaustion, and senescence, have all
been described in T cells from cancer patients (Crespo et al.,
2013; Wherry, 2011)—and chronic TCR stimulation, lack of cos-
timulation, and active suppression by other cells are implicated
in T cell dysfunction. However, whether other mechanisms exist,
or precisely how T cell hyporesponsiveness in tumors is estab-
lished, remains unclear.CNutrient competition between cells can influence cell growth,
survival, and function. A fierce competition likely exists between
cells in the tumor microenvironment, as demand for resources in
this niche is high. Metabolic interplay between tumors and im-
mune cells has been demonstrated. Tumor cells can express
indoleamine 2,3-dioxygenase, an enzyme that depletes trypto-
phan and inhibits T cell proliferation (Munn and Mellor, 2013;
Munn et al., 1999). Tumor-derived lactate can also suppress
T cell function by blocking lactate export (Fischer et al., 2007),
which disrupts their ability to maintain aerobic glycolysis. Aero-
bic glycolysis is required for optimal T cell effector function
(Cham et al., 2008), but not for activation, proliferation, or survival
(Chang et al., 2013). We previously found that in vitro, tumor cells
outcompete T cells for glucose, and this lack of glucose directly
impedes cytokine production that can be critical for tumor clear-
ance. Since many tumors have high rates of glycolysis (Gatenby
and Gillies, 2004; Warburg, 1956), we hypothesized that tumor-
infiltrating CD8+ T lymphocytes (TILs) could experience a loss
of function, due to altered metabolism resulting from tumor-
imposed glucose restriction. We sought to establish whether
glucose competition in the tumor microenvironment, in its own
right, could determine cancer progression by regulating the
‘‘nutrient-fed’’ state of TILs, and thus their functionality.RESULTS
Tumors Glucose-Restrict T Cells, Altering Their
Metabolism and Function
We used an established mouse model of regressing and pro-
gressing tumors (Gubin et al., 2014; Matsushita et al., 2012).
D42m1-T2 (R tumor) is a regressor clone of the d42m1 sarcoma
that expresses the major rejection antigen mutant spectrin-b2.
After transplantation into mice, tumor rejection occurs at day
12 in amanner that depends on IFN-g production from TILs (Mat-
sushita et al., 2012). D42m1-T3 (P tumor) is a progressor clone of
d42m1 that lacks this rejection antigen and grows progressively
after transplantation (Figure 1A). We cultured R or P tumors with
activated C3 T cells, which recognize mutant spectrin-b2
(Matsushita et al., 2012) and measured IFN-g production. We
predicted that regardless of glucose competition, C3 T cells
cultured with R tumor cells might produce more IFN-g, since
they would be stimulated by antigen on the R tumor cells, whileell 162, 1229–1241, September 10, 2015 ª2015 Elsevier Inc. 1229
Figure 1. Tumor-Mediated Glucose Restriction Alters T cell Metabolism and Dampens Their Ability to Produce Cytokine
(A) 13 106 d42m1 derived R or P tumor cells were injected s.c. into 129S6 mice (n = 5). Tumor size is shown as average of two perpendicular diameters ± SEM
from 10 mice of 2 independent experiments.
(B) Activated C3 T cells were cultured alone, or with 1:5 P or R cells for 24h, then PMA/ionomycin stimulated ± 20 mM additional glucose (Glc) for 5h and IFN-g
measured by FACS. % of IFN-g+ T cells (top right) and mean fluorescence intensity (MFI) (vertical); representative ofR 2 independent experiments.
(C) Glucose concentrations in cultures (B) before stimulation; representR 2 independent experiments, shown as mean ± SEM, **p = 0.0087, ***p = 0.0011.
(legend continued on next page)
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C3 T cells cultured alone, or with P tumor cells, would make less
as they would receive no additional stimulation. However, C3
T cells cultured alone produced more IFN-g than when cultured
with R tumor cells, and C3 T cells cultured with P tumor cells
made the least (Figure 1B). Similar results in IFN-g production
were observed when tumors were cultured with activated poly-
clonal T cells (data not shown). Furthermore, IFN-g production
correlated to the amount of glucose that remained in the media
after co-culture (Figure 1C). We added glucose to the co-cul-
tures and IFN-g production significantly increased (Figure 1B),
indicating that glucose utilization, and thus competition for
this sugar, was directly regulating T cell effector function. We
confirmed that the extracellular acidification rate (ECAR) (Nich-
olls et al., 2010), an indicator of aerobic glycolysis, the process
where glucose is converted to lactate in the presence of oxygen,
was higher in the P than the R tumor (Figure 1D, left), supporting
that the P tumor consumes more glucose (Figure 1C). Although
the ECAR of these tumors differed, their rates of proliferation
in vitro were similar (Figure 1D, right), demonstrating that
glycolysis is not directly coupled to proliferation in these cells.
To further explore glucose competition, we impaired R tumor
glycolysis with an inhibitor of mechanistic target of rapamycin
(mTOR) (Kim et al., 2002; Laplante and Sabatini, 2012), or
promoted glycolysis with the Akt activator 4-hydroxytamoxifen
(4-HT) (Doughty et al., 2006; Kohn et al., 1998) (Figure S1A).
We cultured tumor cells with activated OT-I T cells, which recog-
nize Ova peptide and cannot mediate an antigen-specific
response against this tumor, allowing us to assess cytokine
responses independently of antigen-specific stimulation. Upon
PMA/ionomycin stimulation, T cells cultured with rapamycin-
pretreated R tumor cells produced more IFN-g than those with
untreated tumor cells (Figure S1B), while T cells cultured with
4-HT-pretreated R tumor cells produced less IFN-g (Figure S1C).
Adding glucose enhanced IFN-g production in a dose depen-
dent manner (Figure S1C), indicating that tumor and T cells
competed for glucose.
Although R and P tumors differ in antigenicity, tumor-specific
T cells infiltrate both tumors (Gubin et al., 2014; Matsushita et al.,
2012). TILs in the R and P tumors were activated and expressed
T-bet (Figures 1E and 1F, top), suggesting that TILs from either
tumor were transcriptionally competent to produce IFN-g
(Anichini et al., 2010; Parish and Kaech, 2009). However, as
has been shown (Gubin et al., 2014), TILs in the P tumors
were PD-1hi, consistent with hyporesponsiveness (Ahmadzadeh
et al., 2009; Baitsch et al., 2011). Grossly, the immune cell infil-
trates were similar in R and P tumors, although the relative fre-(D) ECAR and R or P tumor proliferation. CellTrace Violet (CTV) labeled cells were
experiments, ***p = 0.001.
(E) R or P tumors were injected s.c. into 129S6 mice and TILs isolated at day 1
(F) CD44, CD62L, PD-1, T-bet, phosphorylated 4E-BP1 (p4E-BP1) and S6K (pS6K
(G) ECAR andOCR/ECAR of ex vivo tumor cells and TILs. OCR (O2 consumption ra
experiments. **p = 0.003, ***p = 0.001.
(H) Maximum glycolytic capacity of TILs. Bar graph shown as mean ± SEM, repr
(I) IFN-g production in TILs measured 5h after PMA/ionomycin stimulation. Contou
independent experiments.
(J) Glucose concentration in extracellular milieu of tumors, ***p = 0.0005. Data a
(K) 2-NBDGwas injected i.v. into tumor-bearingmice and tumors harvested 15mi
mean MFI ± SEM from 3 mice. **p = 0.0147. See also Figure S1.
Cquency of T regulatory (Treg) cells and the balance of M1 versus
M2macrophages differed (Figures S1D–S1F). These results sug-
gested that while activated TILs infiltrate both tumors, TILs in the
P tumor might be hyporesponsive.
We wondered whether higher glycolysis in P tumors limited
glucose in the microenvironment and contributed to TIL hypo-
responsiveness. mTOR is an environmental sensor, and mTOR
pathway signals decrease when nutrients are restricted (Gate-
nby and Gillies, 2004; Kim et al., 2002). We reasoned that
mTOR activity would directly reflect TIL nutrient status. P-TILs
had decreased 4E-BP1 and S6 kinase phosphorylation
compared to R-TILs (Figure 1F, bottom). These data support
the view that P tumors, which consumemore glucose (Figure 1C)
and display higher ECAR (Figure 1D, left), and thus have a higher
glycolytic rate, impose a more severe glucose restriction on TILs
than R tumors.
While many signals exist in tumors that dampen T cells (Fran-
cisco et al., 2010; Keir et al., 2008; Simpson et al., 2013), we
focused on whether metabolic competition in tumors is a funda-
mental force that drives immune cell dysfunction. ECAR of
P-TILs was lower than R-TILs (Figure 1G, left), indicating less
aerobic glycolysis. Unlike R-TILs, P-TILs did not robustly
augment glycolysis when respiration was blocked (Figure 1H).
Ex vivo P tumor cells also exhibited higher ECAR than R tumor
cells (Figure 1G, right), which was inversely proportional to the
metabolism of TILs isolated from that tumor (Figure 1G, left), sug-
gesting a metabolic interplay between tumors and TILs. After re-
stimulation, P-TILs produced less IFN-g than R-TILs (Figure 1I)
and glucose concentration in the P tumor milieu was lower (Fig-
ure 1J). These data link elevated ECAR of P tumors with lower
available glucose in the tumor microenvironment. To directly
address whether P-TILs are glucose-restricted, we injected the
fluorescent glucose analog 2-NBDG and tracked its uptake by
TILs. P-TILs acquired less 2-NBDG than R-TILs (Figure 1K),
which is consistent with their reduced ECAR (Figure 1G, left).
Taken together, these results suggest that TILs are glucose-
restricted in the P tumor and that this could account for their
impaired glycolytic capacity and effector function.
Tumor-Imposed Nutrient Restrictions Can Lead to T Cell
Hyporesponsiveness, Even When Tumors Are Highly
Antigenic
Antigen-specific T cell responses are critical for tumor clearance
(Baitsch et al., 2011; Matsushita et al., 2012) and mutant spec-
trin-b2 expressed by R (but not P) tumors is an important target
for tumor rejection (Matsushita et al., 2012). Given that themeasured for proliferation at day 0 and 3, representative ofR 3 independent
2.
) expression in TILs by FACS, representative ofR 3 independent experiments.
te) is an indicator of OXPHOS. Data shown asmean ±SEM from 3 independent
esentative of 2 independent experiments.
r plots (above) andMFI of IFN-g producing cells (below). Representative ofR 3
veraged from 5 mice.
n later. Histogram (above) depicts TIL 2-NBDG uptake. Bar chart (below) shows
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Figure 2. In Vivo Competition for Glucose
Modulates mTOR Activity and Cytokine Pro-
duction in Antigen-Specific T Cells
(A) 13 106 or 403 106 EL4-Ova cells were injected
i.p. into C57BL/6 mice that received 2 3 104 naive
OT-I Thy1.1+ T cells i.v. Cells in the peritoneal cavity
were assessed at day 7. (B) Phosphorylated 4E-
BP1 (p4E-BP1), S6K (pS6K), and S6 (pS6) of OT-I
T cells assessed by FACS and relative MFI from
mice transplanted with 1 3 106 EL4-Ova cells (1)
or 40 3 106 EL4-Ova cells (40) normalized to MFI
of T cells from mice injected with 1 3 106 EL4-
Ova cells. Bar graphs shown as mean ± SEM
from 4 independent experiments. **p = 0.0085,
***p = 0.001.
(C) IFN-g production by donor OT-I T cells and
CD8+ and CD4+ host T cells 5h post-PMA/ion-
omycin restimulation; % of IFN-g+ T cells (top left)
andMFI of IFN-g+ cells (vertical), representative of 2
independent experiments.
(D) Donor OT-I T cell in vivo IFN-g production. Mice
were injected i.p. with EL4-Ova cells and congenic
naiveOT-I T cells i.v. Mice were injected 7 days later
i.p. with BFA and PBS or glucose, and again 2.5h
later. Cells were harvested 5h after the first injection
and analyzed by FACS. Dot plots show MFI of
IFN-g+ cells relative to mice treated with PBS. Dots
represent individual mice; horizontal bars indicate
mean ± SEM from 2 independent experiments.
*p = 0.0142.antigenicity of R and P tumors differs, we designed experiments
to address how nutrient competition alone could affect TIL activ-
ity. We began by using EL4 tumors that express Ova (EL4-Ova)
and OT-I T cells, allowing us to investigate the impact of nutrient
limitation in T cells with defined antigen specificity. We enhanced
nutrient restriction by increasing tumor cell number. We injected
either 1 3 106 or 40 3 106 EL4-Ova cells intraperitoneally (i.p.)
and then intravenously (i.v.) transferred 2 3 104 naive OT-I
T cells into mice (Figure 2A). OT-I T cells infiltrated the peritoneal
cavities of mice with high or low tumor burdens; however,
they displayed lower mTOR activity in mice injected with 40 3
106 tumor cells (Figure 2B). Moreover, these cells produced
less IFN-g after restimulation, which was also apparent in
endogenous T cells that had entered the peritoneal cavity as
part of the antitumor response (Figure 2C). In attempt to tran-
siently enhance glucose levels in mice that received OT-I
T cells and 40 3 106 EL4-Ova cells, we injected a bolus of
glucose or PBS 2.5 and 5 hr prior to assessing OT-I T cell
IFN-g production. We concurrently injected brefeldin A (BFA)
into these mice to capture in situ IFN-g production. The T cells
in the glucose-injected mice produced more IFN-g (Figure 2D).
These data show that antigen-specific T cell effector function
can be affected by tumor cell numbers and glucose concentra-
tions in vivo, suggesting that tumor-imposed nutrient-restriction
of T cells can contribute to hyporesponsiveness.
Nutrient Competition between Tumors and T Cells Can
Regulate Cancer Progression
The experiments in Figure 2 show that T cell hyporesponsive-
ness developed despite the presence of more antigen, differing1232 Cell 162, 1229–1241, September 10, 2015 ª2015 Elsevier Inc.from published data showing that increases in cell-free antigen
concentrations promote T cell IFN-g production (Constant
et al., 1995). We reasoned that when antigen is sufficient, tumors
might inhibit immunity through nutrient consumption, leaving
TILs at ametabolic disadvantage. We aimed to alter tumor meta-
bolism directly so that we could compare between groups using
the same tumor with equal cell numbers, removing the con-
founding factor of differing antigenicity. Tumor cells cultured
for extended periods of time in low glucose adapt by increasing
respiration (Birsoy et al., 2014), indicating that modulating nutri-
ents can alter metabolism. We cultured R tumor cells in high
glucose (50 mM) and low serum (1% FCS) over several weeks
to select R tumor cells with increased glycolysis (R-1%), while
also culturing the original R tumor in control media (11 mM
glucose, 10% FCS). When returned to control media, the
R-1% tumor cells displayed enhanced ECAR and glucose up-
take compared to the original R tumor cells, although not to
the extent observed in P tumor cells (Figure 3A). We transplanted
R-1% tumors into mice and 10 of 14 recipients developed either
fully progressing tumors, or exhibited delayed regression (Fig-
ures 3B and S2A). At day 20, all 13 of the original R tumors had
regressed, while only 4 of 14 R-1% tumors had fully regressed
(Figures 3B and S2A). The progressing R-1% tumors still ex-
pressed mutant spectrin-b2 (Figures 3C and S2B), indicating
that gain of a ‘‘progressor’’ phenotype in R-1% tumors was not
due to the loss of a dominant epitope recognized by TILs.
Furthermore, R and R-1% tumor cells grow at the same rate
both in vitro (Figure S2C), and in RAG/ mice, which lack B
and T cells (Figure 3D). These data demonstrate that progression
of R-1% tumors was not due to enhanced proliferation or a
tumor-intrinsic survival advantage, but rather due to tumor
imposed impairment of the adaptive immune response.
While there could be differences in the R-1% tumors beyond
glycolysis, we reasoned that they progressed due to their
enhanced glucose uptake (Figure 3A, right). Therefore, we pre-
dicted that manipulating the glycolysis pathway directly should
also turn the R tumor into a progressor tumor. Using a genetic
gain-of-function approach, we transduced R tumors with retro-
virus expressing c-Myc, a transcription factor that drives glycol-
ysis (Gordan et al., 2007). c-Myc expressing R tumors (R-cMyc)
displayed enhanced ECAR in vitro (Figure 3E), compared to R tu-
mors expressing the empty vector (R-EV Ctrl). We also observed
that the R-EV Ctrl tumors displayed higher ECAR than non-
transduced R tumor cells. These data suggested that while the
enhanced glycolysis of R-cMyc tumors should confer a progres-
sor phenotype compared to non-transduced R tumors and R-EV
Ctrl tumors, the R-EV Ctrl tumors could also conceivably exhibit
some progression compared to non-transduced R tumors, due
to their enhanced glycolysis. We transplanted R-cMyc tumors
into mice and 22 of 30 mice (73%) had tumors R5 mm at day
21, while only 5 of 41 mice (12%) with R-EV Ctrl tumors had tu-
mors larger than this size (Figures 3F, S2D). We speculated that
the elevated ECAR in R-EV Ctrl tumors compared to non-trans-
duced R tumors caused progression or delayed regression in a
few mice when compared to non-transduced R tumors, which
normally fully regress by day 21 (Figures 1A and 3B). Therefore,
we compared between groups based on tumor size at day 21.
Importantly, c-Myc expressing R tumors maintained expression
of mutant spectrin-b2 (Figures 3G and S2B). These data show
that in spite of remaining antigenic, c-Myc expressing tumors
became more glycolytic and gained a ‘‘progressor’’ phenotype.
Since c-Myc may drive programs beyond glycolysis, we more
directly tested the role of glucose competition in antigenic tumor
progression. We transduced R tumors with retrovirus expressing
pyruvate dehydrogenase kinase 1 (PDK1), an enzyme that sits
at a key bifurcation point between glycolysis and OXPHOS
(Gerriets et al., 2015). We also transduced R tumor cells with
the glucose transporter Glut1, and hexokinase II (HK2), the first
enzyme in the glycolysis pathway. PDK1-, Glut1-, and HK2-
expressing R tumors (R-PDK1, R-Glut1, and R-HK2) displayed
higher ECAR compared to R-EV Ctrl cells, consistent with
enhanced glycolysis (Figure 3E). When transplanted into mice,
16 of 25 R-PDK1 tumors (64%), 6 of 15 R-Glut1 tumors (40%),
and 10 of 15 R-HK2 tumors (67%) were R5 mm at day 21,
compared to only 5 of 41 R-EV Ctrl tumors (12%) (Figures 3F
and S2D). All tumors expressed mutant spectrin-b2 (Figures
3G and S2B). In addition, activated C3 T cells efficiently killed
the R-1% and the transduced R tumors when in nutrient rich
conditions in vitro, further confirming that these tumors remained
fully antigenic (Figures S2E and S2F). Moreover, the transduced
tumors cultured in vitro (Figure S2G), or in RAG/mice, grew at
fairly similar rates (Figure S2H), indicating that the difference in
progression between the tumors expressing glycolysis genes
versus the EV Ctrl was not only due to differences in growth
rates. We injected 2-NBDG into mice bearing transduced tu-
mors. TILs in tumors expressing glycolysis genes acquired less
glucose than TILs in tumors expressing the EV-Ctrl (Figure 3H).
In co-culture, glycolysis gene transduced tumor cells dampenedCOT-I T cell IFN-g production more than the EV Ctrl transduced
tumors, and the addition of glucose substantially increased
IFN-g production (Figure S2I). Together these results suggest
that tumor cell metabolism can determine cancer progression
by impairing antigen-specific immune responses.
Checkpoint Blockade Therapy Corrects Nutrient
Restriction Experienced by T Cells in a Progressing
Tumor
Checkpoint blockade therapy activates antitumor immunity by
targeting proteins that inhibit T cells (Brahmer et al., 2012; Hamid
et al., 2013; Hodi et al., 2010). This treatment can affect T cell
proliferation (Spranger et al., 2014), function (Spranger et al.,
2014; West et al., 2013), and glucose uptake (Parry et al.,
2005), but the exact mechanisms of how these various treat-
ments work remain unclear (Page et al., 2014). We reasoned
that since these treatments are effective at inducing the regres-
sion of P tumors (Gubin et al., 2014), there should be an effect
on tumor/TIL metabolism after treatment if our proposed model
of metabolic competition in the tumor was correct. We trans-
planted P tumors into mice and treated with isotype control or
CTLA-4, PD-1, or PD-L1 blockade antibodies at days 3, 6, and
9 after transplantation and assessed metabolic parameters
and TIL function on day 12 (Figure 4A). Treatment with all
blockade antibodies resulted in P tumor regression (Figure 4B)
(Gubin et al., 2014) and the isotype had no effect on the outcome
of P or R tumor growth (Figure 4B). We excised tumors on day 12
andmeasured glucose concentrations in the extracellular milieu.
Tumors from blockade antibody-treated mice had more extra-
cellular glucose (similar to that in R tumors) than isotype treated
mice (Figure 4C). In addition, P-TILs from blockade antibody
treated mice had enhanced ECAR compared to TILs from iso-
type treated mice (Figure 4D), correlating glucose availability
in the tumor with glycolysis in TILs. Phosphorylation of mTOR
targets in P-TILs was restored to a level similar to that in
R-TILs (Figure 4E). Finally, the increased glucose in the tumor,
and the greater ECAR observed in TILs, correlated with
increased IFN-g production by the TILs after therapy (Figure 4F).
Our data indicate that blockade therapy corrects the tumor-
induced glucose restriction experienced by TILs and restores
their glycolytic capacity and hence their effector function.
Changes in glucose availability might also be reflected in
changes in TIL OXPHOS. By plotting OCR versus ECAR, we
established a baseline for metabolic fitness of TILs fromR versus
P tumors; thismeasurement emphasized that R-TILs have higher
OXPHOSandglycolysis compared toP-TILs (Figure 4G). CTLA-4
andPD-1 antibodies increasedECARandOCR inP-TILs to levels
equal or above those observed in R-TILs, indicating that these
treatments enhanced the overall metabolic fitness of the TILs.
PD-L1 antibodies. However, primarily promoted aerobic glycol-
ysis, rather than OCR, in the TILs (Figure 4G).
In addition to augmenting the capacity of TILs to compete for
glucose, blockade antibodiesmight increase the ability of TILs to
compete for other substrates. We assessed the protein expres-
sion of glutamate dehydrogenase (Glud1), which catalyzes the
oxidative deamination of glutamate to a-ketoglutarate, an impor-
tant process for energy homeostasis in T cells (Wang et al.,
2011). Glud1 expression was increased in P-TILs from miceell 162, 1229–1241, September 10, 2015 ª2015 Elsevier Inc. 1233
Figure 3. Enhancing Glycolytic Metabolism in Antigenic Tumors That Are Normally Rejected Promotes Tumor Progression
(A) R tumors were cultured in complete media (11 mM glucose and 10% FCS: R) or in high glucose/low FCS media (50 mM and 1% FCS: R-1%) > 3 weeks and
ECAR measured (left). 2-NBDG uptake in tumor cells measured by FACS (right). Data are average of 3 independent experiments, with R and P group values also
used in Figure 5B. 2-NBDG MFI is normalized to R tumor MFI. ECAR data are representative of 3 independent experiments, ***p = 0.001.
(legend continued on next page)
1234 Cell 162, 1229–1241, September 10, 2015 ª2015 Elsevier Inc.
treated with PD-L1 antibodies (Figure S3A). These data suggest
that, in addition to glucose, competition for amino acids, or even
other nutrients and growth factors not examined here, may occur
within tumors, and emphasize the fact that checkpoint blockade
broadly increases the metabolic fitness of TILs, which may be
central to the beneficial effects of these treatments in cancer
therapy.
We speculated that the enhanced glucose in tumors of
treated mice resulted from immune-mediated killing, which led
to reduced tumor cell numbers and thus a reduction in glucose
consumption. It is known that blocking inhibitory receptors
enhances T cell activation (Francisco et al., 2010; Keir et al.,
2008), which might reflect that these treatments allow T cells
to better compete for nutrients like glucose, allowing a greater
engagement of glycolysis by TILs. Consistent with this idea
and published reports (Parry et al., 2005; Patsoukis et al.,
2015; Pedicord et al., 2015; Staron et al., 2014), even treating
in vitro activated T cells, which are already highly glycolytic,
with PD-1 and CTLA-4 antibodies further slightly increased
ECAR (Figures S3B and S3C).
PD-L1 Directly Regulates Tumor Metabolism
IFN-g fromTcells inducesPD-L1on tumors, andPD-L1canallow
the tumor to evade immune mediated attack by inhibiting T cell
function through PD-1/PD-L1 interaction (Francisco et al.,
2010; Keir et al., 2008). While there is a correlation between
PD-L1 expression on melanomas and T cell infiltration (Quezada
and Peggs, 2013), this is not the case for every cancer. Patients
with glioblastoma often have high PD-L1 expression, but this
does not correlate with levels of TILs observed in the tumors
(Berghoff et al., 2014). Also, PD-L1 expression on neurons has
been shown to, through an unknown, but immune-independent
mechanism, kill glioblastoma cells (Liu et al., 2013), and PD-L1
on cancer cells mediated killing of T cells in vitro, which occurred
independently of PD-1 (Dong et al., 2002). Recently, it has been
found that PD-L1 is a direct target of HIF-1a in myeloid-derived
suppressor cells (MDSC). Blockade of PD-L1 under hypoxia
enhanced MDSC-mediated T cell proliferation and function. We
considered the possibility that PD-L1 has a function beyond
negatively signaling to T cells via PD-1.We testedwhether block-
ing PD-L1 on tumors directly altered tumor metabolism. P tumor
cell ECAR, as well as glucose uptake, were reduced after in vitro
treatment with PD-L1 antibodies (Figures 5A and 5B). R tumor
cells, which display lower ECAR than P tumor cells, showed a
smaller reduction in ECAR after treatment (Figure 5A). Antibodies
against major histocompatibility complex-I, another surface pro-
tein, did not affect ECAR (Figure S4A). PD-L1 blockade also in-(B) 129S6 mice were injected s.c. with 1 3 106 R or R-1% tumor cells. Tumor siz
(C) Ex vivo R-1% ‘progressed’ tumors and cultured R and P tumor cell spectrin-
(D) 1 3 106 R or R-1% tumor cells were injected s.c. into Rag/ 129S6 mice an
(E) R tumor cells (R-No Tdx) were transduced with empty retroviral vector (R-EV C
HK2 (R-HK2) and ECAR measured; representR 4 independent experiments. **p =
p = 0.0026 for R-EV Ctrl versus R-Glut1, and p = 0.0196 for R-EV Ctrl versus R-H
(F) 2 3 106 transduced R tumor cells were injected s.c. into 129S6 mice and tum
(G) Spectrin-b2 expression from transduced tumors.
(H) Mice bearing transduced tumors were injected i.v. with 2-NBDG on day 12 an
ratios of TILs-to-tumors normalized to R-EV Ctrl. Dots represent individual mice; h
for R-EV Ctrl versus R-cMyc, p = 0.0065 for R-EV Ctrl versus R-Glut1, and p = 0
Chibited ECAR, to varying degrees, in B16melanoma,MC38 colon
carcinoma, L cells, and progressor clones derived from the
d42m1 parent sarcoma (Figure S4B), suggesting a differential
sensitivity to this treatment among tumors.
We treated P tumor cells with anti-PD-L1 and observed
decreased phosphorylation of mTOR target proteins (Figures
5C and S4C), which correlated with reduced ECAR. Given that
mTOR directly regulates mRNA translation and ribosome
biogenesis (Laplante and Sabatini, 2012), we analyzed protein
expression of several glycolysis enzymes after PD-L1 blockade.
We also assessed Akt phosphorylation, since growth factors
signal to mTOR via Akt. Expression of glycolysis enzymes and
Akt phosphorylation were decreased after anti-PD-L1 treatment
(Figures 5D and S4D). Consistent with the idea that mTOR
affects glycolysis by regulating translation, we found no differ-
ences in transcript levels of key glycolysis genes following anti-
PD-L1 treatment (Figure S4E). These data suggest that PD-L1
regulates the Akt/mTOR pathway, which results in decreased
translation of glycolysis enzymes and thus dampened glycolysis.
We wanted to determine how PD-L1 blockade dampened
mTOR signals in our in vitro system, which is devoid of T cell-ex-
pressed PD-1. We reasoned that PD-L1 antibodies might cause
PD-L1 internalization and resultant cessation of downstream
events. PD-L1 moved from the surface to the interior of the cell
after treatment with anti-PD-L1 for 30 min at 37C, indicating
internalization (Figures 5E and S4F). These results suggest that
surface expressed PD-L1 is important for Akt/mTOR signaling
in tumors.
To confirm that PD-L1 regulates glycolysis, we transduced
P tumors cells with a retrovirus expressing a short-hairpin (hp)
RNA against PD-L1 (PD-L1 hp) to decrease PD-L1 expression.
These tumor cells exhibited reduced ECAR, mTOR pathway
and Akt activity, and glycolysis enzyme expression compared
to cells with a control hairpin (Ctrl hp) (Figures 5F–5H and
S4G). Also, P tumors expressed higher PD-L1 than R tumors
(Figure 5I, upper), which correlated with greater ECAR (Figures
1D and 1G), glucose uptake (Figures 1B and 1J), and glycolysis.
Along with decreased ECAR, PD-L1 shRNA decreased PD-L1
expression (Figure 5I, lower), but did not affect cell proliferation
in vitro (Figure S4H), nor did it affect tumor growth when trans-
planted into RAG/ mice (Figure S4I), suggesting that neither
PD-L1, nor the glycolysis pathway, is necessarily coupled to
tumor cell proliferation. To further verify that PD-L1 expression
on tumors modulated glycolysis, we used retroviral transduction
to generate R tumor clones that expressed different PD-L1 levels
(high and low). High PD-L1 expressing R tumors had greater
ECAR than low PD-L1 expressing tumors (Figure 5J). Togethere is shown as average of two perpendicular diameters ± SEM.
b2 expression. Data presented from 3 individual ex vivo R-1% tumors.
d tumor growth monitored. Data (B and D) from 2 independent experiments.
trl) or vectors expressing c-Myc (R-cMyc), PDK1 (R-PDK1), Glut1 (R-Glut1), or
0.0012 for R-EV Ctrl versus R-cMyc, p = 0.0091 for R-EV Ctrl versus R-PDK1,
K2; ***p = 0.001 for R-No Tdx versus R-EV Ctrl.
or growth monitored for 21 days, representR 3 independent experiments.
d acquisition by TILs and tumor cells measured by FACS. Data shown as MFI
orizontal bars indicate means ±SEM of 3 independent experiments. **p = 0.009
.0066 for R-EV Ctrl versus R-HK2. See also Figure S2.
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Figure 4. T Cells in Progressing Tumors Regain Glycolytic Capacity and Effector Function after Checkpoint Blockade Therapy
(A) 129S6 mice (n = 6-8) were injected s.c. with R or P tumor cells and treated with anti-CTLA-4 (aCTLA-4), anti-PD-1 (aPD-1), anti-PD-L1 (aPD-L1), or isotype
control (Iso) antibody at days 3, 6 and 9 after tumor inoculation.
(B) Tumor size shown as average of two perpendicular diameters ± SEM ofR 3 independent experiments.
(C–E) Glucose concentrations in the extracellular milieu of tumors measured at day 12 (C). Data normalized to R-Iso tumors and depict mean ± SEM from 1–3
independent experiments. *p = 0.0208, **p = 0.0015 (R versus P-Iso), **p = 0.0024, ***p = 0.001. (D) TIL ECAR after checkpoint blockade. Data normalized to R-Iso
tumors and depict mean ±SEM from 3 independent experiments. ***p < 0.001. (E) Phosphorylation of 4E-BP1, S6 and S6K in TILsmeasured by FACS. Bar graphs
(legend continued on next page)
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our data indicate that PD-L1 expression on tumor cells is directly
associated with their glycolytic rate.
Our results suggest that PD-L1 is immunomodulatory, not only
because it delivers a negative signal to T cells via PD-1 (Keir et al.,
2008; Spranger et al., 2014), but also because it enhances tumor
cell glycolysis and thus depletesglucose from immunecells in the
tumor microenvironment. To further support the idea that PD-L1
canmodulate tumor cell metabolism, independently of the adap-
tive immune system, we transplanted PD-L1 expressing tumors
into RAG/ mice and treated with PD-L1 blockade or isotype
antibodies. Glucose levels in the extracellular milieu of excised
tumors isolated from mice that received anti-PD-L1 were higher
compared to isotype treated mice (Figure 5K). Importantly, anti-
PD-L1 treatment of PD-L1-expressing tumors in RAG/ mice
had only a minor effect on reducing tumor size (data not shown),
supporting that in immunocompetentmice, T cellmediatedclear-
ance of tumors is critical (Gubin et al., 2014; Matsushita et al.,
2012). Our results show that expression of PD-L1 on the tumor
cell surface maintains Akt/mTOR signaling, which in turn
supports the translation of glycolysis enzymes and promotes
this metabolic pathway. Our data further indicate that PD-L1
blockade therapy dampens glycolysis in tumors, leaving more
available glucose in the extracellular tumor milieu.
DISCUSSION
Antigen recognition by T cells is critical for tumor clearance, and
stronger antigens lead to stronger activation (Lanzavecchia and
Sallusto, 2002; Rao et al., 2010) and a greater capacity to
compete for nutrients. T cells must acquire adequate nutrients
to engage the metabolism that supports their function. We
(Chang et al., 2013; O’Sullivan and Pearce, 2015; Pearce et al.,
2013), and others (Mellor and Munn, 2008; Mockler et al.,
2014; Srivastava et al., 2010), have speculated that nutrient
competition in the tumor microenvironment in vivo impacts
T cell function. We show here that tumors can dampen TIL func-
tion by competing for glucose, despite the presence of robust
tumor antigens recognized by T cells, demonstrating that meta-
bolic competition, as a distinct mechanism, can lead to T cell
hyporesponsiveness. Although we only directly address glucose
in our study, this model of resource competition likely extends
beyond glucose. Availability of amino acids, fatty acids, and
other metabolites and the presence of growth factors, other
cell types, and costimulatory signals that dictate whether
T cells will express appropriate transporters to allow nutrient
acquisition, will all influence T cell function in tumors. We focus
on IFN-g production from TILs; however, it is likely that a variety
of effector functions, in many immune cell types, might be
dampened in a glucose-depleted environment.
It makes sense that nutrient competition in a tumor shapes the
ability of immune cells to perform in that environment. T cells are(left) shown as mean ± SEM from 4 independent experiments and histograms
**p = 0.0047 (aCTLA-4), **p = 0.0050 (aPD-1). pS6K: **p = 0.0024 (aCTLA-4), **p =
(aPD-L1).
(F) IFN-g production of TILs 5h after PMA/ionomycin restimulation. % of IFN-g+ c
experiments.
(G) OCR versus ECAR (mean ± SEM for both) of TILs after checkpoint blockade.
Cprimed in lymphoid tissues, which are likely nutrient-replete, and
traffic to inflammatory sites where they must compete with other
cells for resources. There they could experience nutrient depri-
vation that impairs their function, but not necessarily their sur-
vival, leading to hyporesponsiveness and cancer progression.
It was shown that TILs specific for defined P tumor antigens infil-
trate the P sarcoma prior to checkpoint blockade; however,
these cells do not produce IFN-g until after therapy (Gubin
et al., 2014), suggesting that conditions in themicroenvironment,
even when antigen is recognized, can dampen T cell function.
This view is consistent with the idea that T cell activation and
costimulation remodel metabolism, endowing the cell with
features that allow it to efficiently compete for nutrients, e.g.,
Glut1 expression (Jacobs et al., 2008). It is not coincidental
that CD28 signaling—the very process that prevents T cell
anergy—functions to increase glucose uptake (Frauwirth et al.,
2002). Tregs andM2macrophages, neither of which require aer-
obic glycolysis but instead use fatty acid oxidation (Huang et al.,
2014; Michalek et al., 2011; Vats et al., 2006), may often appear
in progressing tumors because they can likely survive in low
glucose environments. This is also consistent with observations
that M1 macrophages and effector T cells, both of which use
glycolysis for function (Pearce et al., 2013), appear in regressing
tumors, which might be relatively glucose-replete.
Our data suggest that glucose, which is stably regulated in
metazoans, can become limiting for T cells in the tumor microen-
vironment. We demonstrate that differences in glucose acquisi-
tion between tumors do not necessarily relate to proliferation
differences. It is intriguing to speculate that enhanced glucose
acquisition, or even glycogen storage, is selected for in tumors
(Favaro et al., 2012) to deprive T cells of glucose and thus reduce
the effectiveness of the antitumor response. Our understanding
of how competition for resources, including basic nutrients, is
dynamically regulated in a particular niche and how this imposes
functional changes in cells is only beginning to develop.
Aerobic glycolysis is required for T cells to attain full effector
status, which is regulated by the bi-functional enzyme GAPDH
(Chang et al., 2013). When glucose is present, GAPDH engages
in its enzymatic function; when cells are glucose-restricted,
GAPDH becomes available to bind the 30UTR of IFN-g mRNA,
preventing its efficient translation. When T cells are glucose-
restricted for shorter times, cytokine production can be rescued
by reintroducing glucose, as GAPDHwill re-engage in glycolysis.
However, our preliminary observations indicate that if T cells
experience prolonged nutrient deprivation, dampened cytokine
production becomes relatively irreversible, leading to more per-
manent dysfunction that cannot be corrected through simple
re-exposure to nutrients. Strategies to elevate glucose in an es-
tablished tumor may not necessarily reverse TIL hyporespon-
siveness. TILs might be unable to respond to glucose readily,
for example, if they have not maintained Glut1 expression.(right) representative of 4 independent experiments. p4E-BP1: *p = 0.0249,
0.0025 (aPD-L1). pS6: *p = 0.0145 (aCTLA-4), *p = 0.015 (aPD-1), *p = 0.0134
ells (top left) and MFI of IFN-g+ cells (vertical); representative of 3 independent
Data from 3 independent experiments. See also Figure S3.
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Figure 5. PD-L1 Promotes mTOR Activity and Glycolytic Metabolism in Tumor Cells
R or P tumor cells pre-treated with IFN-g, followed by PD-L1 blockade (aPD-L1) or isotype control (Iso) antibodies. (A) ECAR post-treatment. Data from R 5
independent experiments shown as relative ECAR normalized to R-Iso tumors. ***p = 0.0001.
(B) 2-NBDG uptake by tumor cells measured by FACS. Data from 3 independent experiments normalized to R tumor MFI values. ***p = 0.001. (C) p4E-BP1, pS6K
and pS6 analyzed by western blot; representative of 3 independent experiments; representative histograms of p4E-BP1 and pS6K assessed by FACS.
(D) Akt, phosphorylated Akt (pAkt) and glycolytic enzymes PGK1, TPI, and LDHa examined by western blot; representative of 3 independent experiments.
(E) R tumor clones expressing high levels of PD-L1 were treated with anti-PD-L1 antibody (aPD-L1) for 15min on ice, then kept on ice (0min) or incubated at 37C
for 30min (30min) andwashed in acidic solution to dissociate antibody from the cell surface (+ acid wash) or left untreated (no acid wash). After fixation, cells were
incubated with anti-Rat IgG A488 (red) to detect aPD-L1 on the cell surface. After permeabilization, cells were incubated with anti-Rat IgG A647 (yellow) to detect
surface expressed and internalized aPD-L1 and nuclear stained (blue). Cells imaged by confocal microscopy. Data representative of 4 independent experiments.
(F) ECAR of tumor cells transduced with pdl1 shRNA (PD-L1 hp) or control hp against luciferase (Ctrl hp). From 2 independent experiments represented as relative
ECAR normalized to R Ctrl hp cells, ***p < 0.0001.
(G) p4E-BP1, pS6, and pS6K examined by western blot; representative of 3 independent experiments.
(legend continued on next page)
1238 Cell 162, 1229–1241, September 10, 2015 ª2015 Elsevier Inc.
Also, if the metabolic balance between tumors and TILs is not
perturbed in favor of the T cells prior to glucose exposure, the
tumor will likely continue to outcompete the T cells, even when
more available glucose is present (O’Sullivan and Pearce,
2015). Our current studies are aimed at understanding how
metabolic restrictions in vivo can lead to long-term hyporespon-
siveness in T cells.
We envisage that the various states of T cell hyporesponsive-
ness that have been described in cancer and infection may be
induced by an initial metabolic restriction. This could manifest
from a shortage of glucose, or from any signal, or lack of signal,
to the T cell that abrogates its ability to acquire glucose. If this
model were correct, then there might only be a narrow window
of time during which T cells already present in a tumor could
be targeted to regain function. Strategies that aim to deplete
tumor-promoting immune cells in a tumor, coupled with those
that promote glycolysis in newly infiltrating T cells, may be
the most effective way to metabolically remodel the tumor
microenvironment. This could explain why combining check-
point blockade therapies that target CTLA-4, which depletes
tumor Treg cells (Simpson et al., 2013), with those against
PD-1, are particularly effective (Hamid et al., 2013; Wolchok
et al., 2013).
Our data suggest that checkpoint blockade antibodies that
affect glucose metabolism might be most effective against
tumors with higher glycolytic rates. It is likely that tumors that
rely more on OXPHOS and use diverse substrates for fuel might
not starve the microenvironment of glucose and thus would be
less affected by these therapies. These results could explain
why these therapies do not work for some patients. We are
investigating whether the glycolytic rate of a tumor could be
used as a prognostic tool to determine the efficacy of these
treatments.
Our finding that PD-L1 regulates tumor metabolism was
serendipitous. Although PD-L1 is known to inhibit T cells via
PD-1, it has remained unclear whether it serves additional bio-
logical advantages for tumors (Carlsson and Issazadeh-Navikas,
2014). Consistent with our findings that PD-L1 has T cell inde-
pendent function, it has been shown that neurons can inhibit as-
trocytoma cell proliferation (Hatten and Shelanski, 1988) and that
killing of murine glioblastoma cells is dependent on expression
and activity of PD-L1 on neurons (Issazadeh-Navikas, 2013;
Kingwell, 2013). The precise mechanism by which these events
occur is unknown; however, PD-L1 might confer higher glycol-
ysis to one cell type, e.g., neurons, which allowed them to
deplete glucose from, and subsequently lead to the dampened
survival of another cell type, e.g., cancer cells.
The 30 amino acid cytoplasmic tail of PD-L1 is highly
conserved, which suggests functional significance (Francisco(H) Western blot of Akt, pAkt, PGK1, LDHa, and TPI; representative of 3 indepen
(I) PD-L1 expression on IFN-g pre-treated R or P tumor cells (top) or on PD-L1 h
(J) ECAR of R tumors expressing high (Hi) and low (Lo) levels of surface PD-L1 afte
2 independent experiments.
(K) Rag/micewere injected s.c. with 23 106 R-PD-L1 expressing tumor cells, fo
transplantation. Extracellular glucose was measured at day 12. Dots represent
experiments. *p = 0.0319. Figures 5D, H, and Figures S4D, G contain separate b
necessitated separate probing. See also Figure S4.
Cet al., 2010; Keir et al., 2008). Our data show that PD-L1
shRNA-mediated knockdown phenocopies our results with
PD-L1 blockade antibody, which decreases expression of sur-
face PD-L1 via receptor internalization. Experiments are under-
way to identify how surface PD-L1 signals to Akt and mTOR,
and which proteins might be involved in this process. It is
conceivable that the cytoplasmic tail of PD-L1 is posttranslation-
ally modified to facilitate its interaction with other proteins that
relay information to mTOR. Likewise, it is also possible that
PD-L1 sits in a cell membrane domain that promotes its associ-
ation with other signaling proteins. This would not necessarily be
dependent on any signaling capacity inherent to the cytoplasmic
domain, but rather accessory proteins could signal to mTOR.We
envisage that if PD-L1 is not expressed at the surface, its asso-
ciation with other proteins in the membrane is destabilized, and
signaling tomTOR is blunted. Morework is required to determine
exactly how PD-L1 signals.
In summary, we have shown that glucose competition
between tumors and T cells can directly influence cancer pro-
gression and have discovered an unexpected role for PD-L1 in
regulating tumor cell metabolism. New efforts to target cancer
should incorporate the idea that metabolic competition occurs
in tumors and this can influence tumor progression. Future ther-
apies may consider combining treatments that dampen tumor
metabolism with those that enhance TIL nutrient acquisition in
order to promote optimal antitumor immunity.
EXPERIMENTAL PROCEDURES
Mice and Tumor Transplantation
129S6 mice from Taconic Farms and C57BL/6 mice from The Jackson Labo-
ratory were used for all experiments. Unless otherwise indicated, 1–2 3 106 R
or P tumor cells were injected subcutaneously (s.c.) into the right flank of mice.
Sarcoma tumors were excised from mice at 12 days (d10–d13) post-trans-
plantation. Isolated tumors were chopped and digested in type IA collagenase
and DNase I at 37C.
In Vivo Checkpoint Blockade Treatment
Tumor bearing mice were injected i.p. with 200 mg of aCTLA4 (9H10) or aPD-1
(RMP1-14) or aPD-L1 (10F.9G2) or with isotype control antibodies on days 3,
6, and 9 after tumor transplantation.
Metabolism Assay
OCR and ECAR were analyzed on a XF96 Extracellular Flux Analyzer
(Seahorse Bioscience). Cells were plated in nonbuffered RPMI 1640 media
with 25 mM glucose. Measurements were obtained under basal conditions
and after the addition of 1 mM oligomycin (maximum glycolytic capacity).
Transduction
Tumor cells were transduced with GFP-reporting virus expressing shRNA
against luciferase (Ctrl hp) or shRNA against CD274 (PD-L1 hp) in media con-
taining 8 mg/ml Polybrene (Sigma) and 20 mM HEPES (Hyclone) for 5 hr,dent experiments.
p or Ctrl hp transduced tumor cells treated with anti-PD-L1 (bottom).
r transduction with PD-L1 expressing retrovirus, represented asmean ±SEM of
llowed by treatment with PD-L1 antibodies (aPD-L1) at days 2, 5, 8 and 11 after
individual mice; horizontal bars indicate means ± SEM from 2 independent
lots from equally loaded lanes due to similar sizes of glycolysis enzymes that
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followed by additional transduction with the same virus overnight. Transduced
tumor cells were sorted by GFP expression. R tumor cells were transduced
with retrovirus expressing c-Myc, PDK1, Glut1, or HK2, or with empty vector.
Glucose Assay
Glucose concentrations in the supernatant were measured by the Glucose
Assay Kit (Eton Bioscience). For ex vivo glucose levels, harvested tumors
were weighed and minced in fixed amounts of PBS. Glucose concentration
was quantified in accordance with the weight of tumors and the volume of
collected supernatant, and normalized with glucose concentrations in R
tumors.
Statistical Analysis
Comparisons for two groups were calculated by using an unpaired, two-tailed
Student’s t test. Comparisons for more than two groups were calculated using
1-way ANOVA followed by Bonferroni’s multiple comparison tests.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cell.2015.08.016.
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